

## **Theramine Selected References**

1. Borgonio A, Witte K, Stahrenberg R, Lemmer B. Influence of circadian time, ageing, and hypertension on the urinary excretion of nitric oxide metabolites in rats. *Mech Ageing Dev* 1999 November 2;111(1):23-37.
2. Cesaro P, Ollat H. Pain and its treatments. *Eur Neurol* 1997;38(3):209-15.
3. Aghabeigi B. The pathophysiology of pain. *Br Dent J* 1992 August 8;173(3):91-7.
4. Zimmermann M. Pathobiology of neuropathic pain. *Eur J Pharmacol* 2001 October 19;429(1-3):23-37.
5. Sawynok J, Reid A. Interactions of descending serotonergic systems with other neurotransmitters in the modulation of nociception. *Behav Brain Res* 1996;73(1-2):63-8.
6. Lewis DA. Anti-inflammatory drugs from plant and marine sources. *Agents Actions Suppl* 1989;27:3-373.
7. Manthey JA. Biological properties of flavonoids pertaining to inflammation. *Microcirculation* 2000;7(6 Pt 2):S29-S34.
8. Friedrich MJ. Loss of nerve: a molecular approach to better treatment of chronic pain. *JAMA* 2000 January 12;283(2):187-8.
9. Karlsten R, Gordh T. How do drugs relieve neurogenic pain? *Drugs Aging* 1997 November;11(5):398-412.
10. Cashman JN. The mechanisms of action of NSAIDs in analgesia. *Drugs* 1996;52 Suppl 5:13-23.
11. Dumka VK, Tandan SK, Tripathi HC, Raviprakash V. Central serotonergic and histaminergic modulation of peripheral inflammation and nociception in rats. *Indian J Physiol Pharmacol* 1996 April;40(2):163-6.
12. Okamoto K, Imbe H, Morikawa Y et al. 5-HT<sub>2A</sub> receptor subtype in the peripheral branch of sensory fibers is involved in the potentiation of inflammatory pain in rats. *Pain* 2002 September;99(1-2):133-43.
13. Alhaider AA, Lei SZ, Wilcox GL. Spinal 5-HT<sub>3</sub> receptor-mediated antinociception: possible release of GABA. *J Neurosci* 1991 July;11(7):1881-8.
14. Williams M, Kowaluk EA, Arneric SP. Emerging molecular approaches to pain therapy. *J Med Chem* 1999 May 6;42(9):1481-500.
15. Conlay LA, Zeisel SH. Neurotransmitter precursors and brain function. *Neurosurgery* 1982 April;10(4):524-9.
16. Bach-Rojecky L. Analgesic effect of caffeine and clomipramine: a possible interaction between adenosine and serotonin systems. *Acta Pharm* 2003 March;53(1):33-9.
17. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. *Annu Rev Neurosci* 2001;24:31-55.

18. Fernstrom JD. Effects on the diet on brain neurotransmitters. *Metabolism* 1977 February;26(2):207-23.
19. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. *Annu Rev Neurosci* 1991;14:219-45.
20. Willis WD. Role of neurotransmitters in sensitization of pain responses. *Ann N Y Acad Sci* 2001 March;933:142-56.
21. Furst S. Transmitters involved in antinociception in the spinal cord. *Brain Res Bull* 1999 January 15;48(2):129-41.
22. Belousov AB, O'Hara BF, Denisova JV. Acetylcholine becomes the major excitatory neurotransmitter in the hypothalamus in vitro in the absence of glutamate excitation. *J Neurosci* 2001 March 15;21(6):2015-27.
23. Farber L, Haus U, Spath M, Drechsler S. Physiology and pathophysiology of the 5-HT<sub>3</sub> receptor. *Scand J Rheumatol Suppl* 2004;(119):2-8.
24. Dickenson AH, Chapman V, Green GM. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. *Gen Pharmacol* 1997;28:633-638.
25. Ebersberger A. Physiology of meningeal innervation: aspects and consequences of chemosensitivity of meningeal nociceptors. *Microsc Res Tech* 2001 April 15;53(2):138-46.
26. Aley KO, McCarter G, Levine JD. Nitric oxide signaling in pain and nociceptor sensitization in the rat. *J Neurosci* 1998 September 1;18(17):7008-14.
27. Sutherland SP, Cook SP, McCleskey EW. Chemical mediators of pain due to tissue damage and ischemia. *Prog Brain Res* 2000;129:21-38.
28. Herrero JF, Laird JM, Lopez-Garcia JA. Wind-up of spinal cord neurones and pain sensation: much ado about something? *Prog Neurobiol* 2000 June;61(2):169-203.
29. Linderoth B, Stiller CO, Gunasekera L et al. Release of neurotransmitters in the CNS by spinal cord stimulation: survey of present state of knowledge and recent experimental studies. *Stereotact Funct Neurosurg* 1993;61(4):157-70.
30. Canavero S, Bonicalzi V. The neurochemistry of central pain: evidence from clinical studies, hypothesis and therapeutic implications. *Pain* 1998 February;74(2-3):109-14.
31. Ono T, Inoue M, Rashid MH, Sumikawa K, Ueda H. Stimulation of peripheral nociceptor endings by low dose morphine and its signaling mechanism. *Neurochem Int* 2002 December;41(6):399-407.
32. Oliverio A, Castellano C, Puglisi-Allegra S. Psychobiology of opioids. *Int Rev Neurobiol* 1984;25:277-337.
33. Chevlen E. Opioids: a review. *Curr Pain Headache Rep* 2003 February;7(1):15-23.
34. International Symposium on Substance P and Related Peptides: Pain, Inflammation, Visceral and CNS Functions. Proceedings. Shizuoka, Japan, November 3-6, 1992. *Regul Pept* 1993 July 2;46(1-2):1-471.

35. Gracely RH. Pain measurement. *Acta Anaesthesiol Scand* 1999 October;43(9):897-908.
36. Furst DE, Manning DC. Future directions in pain management. *Clin Exp Rheumatol* 2001 November;19(6 Suppl 25):S71-S76.
37. Almay BG, Johansson F, Von Knorring L, Le Greves P, Terenius L. Substance P in CSF of patients with chronic pain syndromes. *Pain* 1988 April;33(1):3-9.
38. Bellinger FP, Wilce PA, Bedi KS, Wilson P. Long-lasting synaptic modification in the rat hippocampus resulting from NMDA receptor blockade during development. *Synapse* 2002 February;43(2):95-101.
39. Abbadie C, Brown JL, Mantyh PW, Basbaum AI. Spinal cord substance P receptor immunoreactivity increases in both inflammatory and nerve injury models of persistent pain. *Neuroscience* 1996 January;70(1):201-9.
40. DeVane CL. Substance P: a new era, a new role. *Pharmacotherapy* 2001 September;21(9):1061-9.
41. Harrison S, Geppetti P. Substance p. *Int J Biochem Cell Biol* 2001 June;33(6):555-76.
42. Liu H, Mantyh PW, Basbaum AI. NMDA-receptor regulation of substance P release from primary afferent nociceptors. *Nature* 1997 April 17;386(6626):721-4.
43. Afrah AW, Stiller CO, Olgart L, Brodin E, Gustafsson H. Involvement of spinal N-methyl-D-aspartate receptors in capsaicin-induced in vivo release of substance P in the rat dorsal horn. *Neurosci Lett* 2001 December;316(2):83-6.
44. Dickenson AH. NMDA receptor antagonists: interactions with opioids. *Acta Anaesthesiol Scand* 1997 January;41(1 Pt 2):112-5.
45. Hunt SP. Pain control: breaking the circuit. *Trends Pharmacol Sci* 2000 August;21(8):284-7.
46. Oliver KR, Sirinathsinghji DJ, Hill RG. From basic research on neuropeptide receptors to clinical benefit. *Drug News Perspect* 2000 November;13(9):530-42.
47. Brown CR. Pain management. Psychologic aspects of pain. *Pract Periodontics Aesthet Dent* 1997 March;9(2):178.
48. Sorkin LS, Wallace MS. Acute pain mechanisms. *Surg Clin North Am* 1999 April;79(2):213-29.
49. Dickenson AH. Central acute pain mechanisms. *Ann Med* 1995 April;27(2):223-7.
50. Buzsaki G, Draguhn A. Neuronal oscillations in cortical networks. *Science* 2004 June 25;304(5679):1926-9.
51. Dickenson AH. Plasticity: implications for opioid and other pharmacological interventions in specific pain states. *Behav Brain Sci* 1997 September;20(3):392-403.
52. Malan TP, Mata HP, Porreca F. Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain. *Anesthesiology* 2002 May;96(5):1161-7.
53. Gu Y, Huang LY. Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons. *Neurosci Lett* 2002 May 24;324(3):177-80.

54. Aanonsen LM, Wilcox GL. Muscimol, gamma-aminobutyric acidA receptors and excitatory amino acids in the mouse spinal cord. *J Pharmacol Exp Ther* 1989 March;248(3):1034-8.
55. Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. *Clin J Pain* 2002 November;18(6 Suppl):S125-S132.
56. Bhoola KD, Elson CJ, Dieppe PA. Kinins--key mediators in inflammatory arthritis? *Br J Rheumatol* 1992 August;31(8):509-18.
57. Chauhan A, More RS, Mullins PA, Taylor G, Petch C, Schofield PM. Aging-associated endothelial dysfunction in humans is reversed by L-arginine. *J Am Coll Cardiol* 1996 December;28(7):1796-804.
58. Decker MW, Meyer MD, Sullivan JP. The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. *Expert Opin Investig Drugs* 2001 October;10(10):1819-30.
59. DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. *Curr Drug Targets* 2000 July;1(1):25-58.
60. Nathan P. Can the cognitive enhancing effects of ginkgo biloba be explained by its pharmacology? *Med Hypotheses* 2000 December;55(6):491-3.
61. Thomas RJ. Excitatory amino acids in health and disease. *J Am Geriatr Soc* 1995 November;43(11):1279-89.
62. Cocchi R. A syndrome from a possible GABA deficiency. Clinical-therapeutic report on 15 cases. *Acta Psychiatr Belg* 1978 March;78(2):407-24.
63. Ford-Hutchinson AW. Regulation of leukotriene biosynthesis. *Cancer Metastasis Rev* 1994;13:257-267.
64. Cantin AM, Begin R. Glutathione and inflammatory disorders of the lung. *Lung* 1991;169:123-138.
65. Eide PK, Hole K. Subsensitivity of serotonin and substance P receptors involved in nociception after repeated administration of a serotonin receptor agonist. *J Neural Transm* 1989;77(1):1-10.
66. Alnigenis MN, Barland P. Fibromyalgia syndrome and serotonin. *Clin Exp Rheumatol* 2001 March;19(2):205-10.
67. Costall B, Naylor RJ. 5-HT<sub>3</sub> receptors. *Curr Drug Targets CNS Neurol Disord* 2004 February;3(1):27-37.
68. Eide PK, Hole K. Interactions between serotonin and substance P in the spinal regulation of nociception. *Brain Res* 1991 June 7;550(2):225-30.
69. Goettl VM, Huang Y, Hackshaw KV, Stephens RL, Jr. Reduced basal release of serotonin from the ventrobasal thalamus of the rat in a model of neuropathic pain. *Pain* 2002 September;99(1-2):359-66.
70. Juhl JH. Fibromyalgia and the serotonin pathway. *Altern Med Rev* 1998 October;3(5):367-75.
71. Ernberg M, Lundeberg T, Kopp S. Pain and allodynia/hyperalgesia induced by intramuscular injection of serotonin in patients with fibromyalgia and healthy individuals. *Pain* 2000 March;85(1-2):31-9.

72. Ahmadi S, Muth-Selbach U, Lauterbach A, Lipfert P, Neuhuber WL, Zeilhofer HU. Facilitation of spinal NMDA receptor currents by spillover of synaptically released glycine. *Science* 2003 June 27;300(5628):2094-7.
73. Xu M, Petraschka M, McLaughlin JP et al. Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. *J Neurosci* 2004;24:4576-4584.
74. Budzinski M, Misterek K, Gumulka W, Dorociak A. Inhibition of inducible nitric oxide synthase in persistent pain. *Life Sci* 2000;66(4):301-5.
75. Holthusen H, Arndt JO. Nitric oxide evokes pain at nociceptors of the paravascular tissue and veins in humans. *J Physiol* 1995 August 15;487 ( Pt 1):253-8.
76. Mizutani T, Layon AJ. Clinical applications of nitric oxide. *Chest* 1996 August;110(2):506-24.
77. Pelligrino DA, Baughman VL, Koenig HM. Nitric oxide and the brain. *Int Anesthesiol Clin* 1996;34(4):113-32.
78. Hirasawa N, Ohuchi K, Kawarasaki K, Watanabe M, Tsurufuji S. Occurrence of histamine-production-increasing factor in the postanaphylactic phase of allergic inflammation. *Int Arch Allergy Appl Immunol* 1989;88(4):386-93.
79. Galeotti N, Ghelardini C, Bartolini A. Antihistamine antinociception is mediated by Gi-protein activation. *Neuroscience* 2002;109(4):811-8.
80. Batmanghelidj F. Pain: a need for paradigm change. *Anticancer Res* 1987 September;7(5B):971-89.
81. Jacobson KA, Moro S, Manthey JA, West PL, Ji XD. Interactions of flavones and other phytochemicals with adenosine receptors. *Adv Exp Med Biol* 2002;505:163-71.
82. Sawynok J. Adenosine receptor activation and nociception. *Eur J Pharmacol* 1998 April 17;347(1):1-11.
83. Ribeiro JA, Sebastiao AM, de Mendonca A. Adenosine receptors in the nervous system: pathophysiological implications. *Prog Neurobiol* 2002 December;68(6):377-92.
84. Luceri C, Caderni G, Sanna A, Dolara P. Red wine and black tea polyphenols modulate the expression of cyclooxygenase-2, inducible nitric oxide synthase and glutathione-related enzymes in azoxymethane-induced f344 rat colon tumors. *J Nutr* 2002 June;132(6):1376-9.
85. Sovak M. Grape Extract, Resveratrol, and Its Analogs: A Review. *J Med Food* 2001;4(2):93-105.
86. Dongmo AB, Nguetefack T, Lacaille-Dubois MA. Antinociceptive and anti-inflammatory activities of *Acacia pennata* wild (Mimosaceae). *J Ethnopharmacol* 2005 April 8;98(1-2):201-6.
87. Ha E, Zemel MB. Functional properties of whey, whey components, and essential amino acids: mechanisms underlying health benefits for active people (review). *J Nutr Biochem* 2003;14:251-258.
88. Yalcin AS. Emerging therapeutic potential of whey proteins and peptides. *Curr Pharm Des* 2006;12:1637-1643.
89. Teschemacher H. Opioid receptor ligands derived from food proteins. *Curr Pharm Des* 2003;9:1331-1344.

90. Richelle M, Tavazzi I, Offord E. Comparison of the antioxidant activity of commonly consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving. *J Agric Food Chem* 2001 July;49(7):3438-42.
91. Nagaoka H, Sakurada S, Sakurada T et al. Theophylline-induced nociceptive behavioral response in mice: possible indirect interaction with spinal N-methyl-D-aspartate receptors. *Neurochem Int* 1993 January;22(1):69-74.
92. Conlay LA, Conant JA, deBros F, Wurtman R. Caffeine alters plasma adenosine levels. *Nature* 1997 September 11;389(6647):136.
93. Schwarzschild MA, Chen JF, Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. *Neurology* 2002 April 23;58(8):1154-60.
94. Zeisel SH. Dietary influences on neurotransmission. *Adv Pediatr* 1986;33:23-47.
95. Seltzer S, Marcus R, Stoch R. Perspectives in the control of chronic pain by nutritional manipulation. *Pain* 1981 October;11(2):141-8.
96. Fernstrom JD. Dietary precursors and brain neurotransmitter formation. *Annu Rev Med* 1981;32:413-25.
97. Fernstrom JD. Can nutrient supplements modify brain function? *Am J Clin Nutr* 2000 June;71(6 Suppl):1669S-75S.
98. Fernstrom JD. Dietary amino acids and brain function. *J Am Diet Assoc* 1994 January;94(1):71-7.
99. Lehnert H, Wurtman RJ. Amino acid control of neurotransmitter synthesis and release: physiological and clinical implications. *Psychother Psychosom* 1993;60(1):18-32.
100. Wurtman RJ. Dietary treatments that affect brain neurotransmitters. Effects on calorie and nutrient intake. *Ann N Y Acad Sci* 1987;499:179-90.
101. Wurtman RJ. Nutrients affecting brain composition and behavior. *Integr Psychiatry* 1987 December;5(4):226-38.
102. Anderson GH, Johnston JL. Nutrient control of brain neurotransmitter synthesis and function. *Can J Physiol Pharmacol* 1983 March;61(3):271-81.
103. Kris-Etherton PM, Lefevre M, Beecher GR, Gross MD, Keen CL, Etherton TD. Bioactive compounds in nutrition and health-research methodologies for establishing biological function: the antioxidant and anti-inflammatory effects of flavonoids on atherosclerosis. *Annu Rev Nutr* 2004;24:511-38.
104. Boer J, Duyvendak M, Schuurman FE, Pouw FM, Zaagsma J, Meurs H. Role of L-arginine in the deficiency of nitric oxide and airway hyperreactivity after the allergen-induced early asthmatic reaction in guinea-pigs. *Br J Pharmacol* 1999 November;128(5):1114-20.
105. Cooke JP, Oka RK. Atherogenesis and the arginine hypothesis. *Curr Atheroscler Rep* 2001 May;3(3):252-9.
106. Tangphao O, Chalon S, Coulston AM et al. L-arginine and nitric oxide-related compounds in plasma: comparison of normal and arginine-free diets in a 24-h crossover study. *Vasc Med* 1999;4(1):27-32.

107. Cerra FB. Nutrient modulation of inflammatory and immune function. *Am J Surg* 1991 February;161(2):230-4.
108. Fernstrom JD. Effects of the diet and other metabolic phenomena on brain tryptophan uptake and serotonin synthesis. *Adv Exp Med Biol* 1991;294:369-76.
109. Kahkonen S, Ahveninen J, Pennanen S, Liesivuori J, Ilmoniemi RJ, Jaaskelainen IP. Serotonin modulates early cortical auditory processing in healthy subjects: evidence from MEG with acute tryptophan depletion. *Neuropsychopharmacology* 2002 November;27(5):862-8.
110. Pant KC, Rogers QR, Harper AE. Plasma and tissue free amino acid concentrations in rats fed tryptophan-imbalanced diets with or without niacin. *J Nutr* 1974 December;104(12):1584-96.
111. Sahakian BJ, Wurtman RJ, Barr JK, Millington WR, Chiel HJ. Low tryptophan diet decreases brain serotonin and alters response to apomorphine. *Nature* 1979 June 21;279(5715):731-2.
112. Angel-Meza AR, Ramirez-Cortes L, Adame-Gonzalez IG, Gonzalez B, I, Beas-Zarate C. Cerebral GABA release and GAD activity in protein- and tryptophan- restricted rats during development. *Int J Dev Neurosci* 2002 February;20(1):47-54.
113. Handler P, Bernheim F. Influence of dietary factors on hypertension induced by choline deficiency. *Am J Physiol* 1950 July 1;162(1):189-92.
114. Kuksis A, Mookerjee S. Choline. *Nutr Rev* 1978 July;36(7):201-7.
115. Alexander JW. Specific nutrients and the immune response. *Nutrition* 1995 March;11(2 Suppl):229-32.
116. Field CJ, Johnson I, Pratt VC. Glutamine and arginine: immunonutrients for improved health. *Med Sci Sports Exerc* 2000 July;32(7 Suppl):S377-S388.
117. Regulation of serine dehydratase and phosphoglycerate dehydrogenase by proteins and essential amino acids. *Nutr Rev* 1974 March;32(3):88-9.
118. de Koning TJ, Klomp LW. Serine-deficiency syndromes. *Curr Opin Neurol* 2004 April;17(2):197-204.
119. Histidine: An essential amino acid for normal adults. *Nutr Rev* 1975 July;33(7):200-2.
120. Antener I, Verwilghen AM, Van GC, Mauron J. Biochemical study of malnutrition. Part VI: Histidine and its metabolites. *Int J Vitam Nutr Res* 1983;53(2):199-209.
121. Timiras PS, Hudson DB, Segall PE. Lifetime brain serotonin: regional effects of age and precursor availability. *Neurobiol Aging* 1984;5(3):235-42.
122. Brown DW. Abnormal fluctuations of acetylcholine and serotonin. *Med Hypotheses* 1993 May;40(5):309-10.
123. Nelson SR, Walaszek EJ. Pharmacology of the central nervous system. *Prog Neurol Psychiatry* 1969;24:131-52.
124. Wurtman RJ. When--and why--should nutritional state control neurotransmitter synthesis? *J Neural Transm Suppl* 1979;(15):69-79.

125. Adibi SA, Modesto TA, Morse EL, Amin PM. Amino acid levels in plasma, liver, and skeletal muscle during protein deprivation. *Am J Physiol* 1973 August;225(2):408-14.
126. Sendur OF, Turan Y, Tastaban E, Yenisey C, Serter M. Serum antioxidants and nitric oxide levels in fibromyalgia: a controlled study. *Rheumatol Int* 2008.
127. Jegerschold C, Pawelzik SC, Purhonen P et al. Structural basis for induced formation of the inflammatory mediator prostaglandin E2. *Proc Natl Acad Sci U S A* 2008;105:11110-11115
128. Barbarosie M, Louvel J, D'Antuono M, Kurcewicz I, Avoli M. Masking synchronous GABA-mediated potentials controls limbic seizures. *Epilepsia* 2002 December;43(12):1469-79.
129. Berretta N, Paolucci E, Bernardi G, Mercuri NB. Glutamate receptor stimulation induces a persistent rhythmicity of the GABAergic inputs to rat midbrain dopaminergic neurons. *Eur J Neurosci* 2001 September;14(5):777-84.
130. Ernberg M, Hedenberg-Magnusson B, Alstergren P, Lundeberg T, Kopp S. Pain, allodynia, and serum serotonin level in orofacial pain of muscular origin. *J Orofac Pain* 1999;13(1):56-62.
131. Fernstrom JD, Wurtman RJ. Control of brain serotonin levels by the diet. *Adv Biochem Psychopharmacol* 1974;11(0):133-42.
132. Fernstrom JD, Fernstrom MH. Diet, monoamine neurotransmitters and appetite control. *Nestle Nutr Workshop Ser Clin Perform Programme* 2001;(5):117-31.
133. Byerley WF, Risch SC. Depression and serotonin metabolism: rationale for neurotransmitter precursor treatment. *J Clin Psychopharmacol* 1985 August;5(4):191-206.
134. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Wall K. Serum amino acids in fibrositis/fibromyalgia syndrome. *J Rheumatol Suppl* 1989 November;19:158-63.
135. Delgado PL, Charney DS, Price LH, Landis H, Heninger GR. Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects. *Life Sci* 1989;45(24):2323-32.
136. Efron DT, Barbul A. Modulation of inflammation and immunity by arginine supplements. *Curr Opin Clin Nutr Metab Care* 1998 November;1(6):531-8.
137. Efron DT, Barbul A. Arginine and immunonutrition: a reevaluation. *Nutrition* 2000 January;16(1):73-4.
138. Evoy D, Lieberman MD, Fahey TJ, III, Daly JM. Immunonutrition: the role of arginine. *Nutrition* 1998 July;14(7-8):611-7.
139. Pita AM, Fernandez-Bustos A, Rodes M et al. Orotic aciduria and plasma urea cycle-related amino acid alterations in short bowel syndrome, evoked by an arginine-free diet. *JPEN J Parenter Enteral Nutr* 2004 September;28(5):315-23.
140. Cho ES, Anderson HL, Wixom RL, Hanson KC, Krause GF. Long-term effects of low histidine intake on men. *J Nutr* 1984 February;114(2):369-84.
141. Pestana A. Dietary and hormonal control of enzymes of amino acid catabolism in liver. *Eur J Biochem* 1969 December;11(2):400-4.



142. Wan Y, Vinson JA, Etherton TD, Proch J, Lazarus SA, Kris-Etherton PM. Effects of cocoa powder and dark chocolate on LDL oxidative susceptibility and prostaglandin concentrations in humans. *Am J Clin Nutr* 2001 November;74(5):596-602.
143. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. *J Nutr* 2000 August;130(8S Suppl):2073S-85S.
144. Damas J, Bourdon V, Remacle-Volon G, Lecomte J. Pro-inflammatory flavonoids which are inhibitors of prostaglandin biosynthesis. *Prostaglandins Leukot Med* 1985 July;19(1):11-24.
145. Lindahl M, Tagesson C. Flavonoids as phospholipase A2 inhibitors: importance of their structure for selective inhibition of group II phospholipase A2. *Inflammation* 1997 June;21(3):347-56.
146. Mandel S, Youdim MB. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. *Free Radic Biol Med* 2004 August 1;37(3):304-17.
147. Rein D, Paglieroni TG, Pearson DA et al. Cocoa and wine polyphenols modulate platelet activation and function. *J Nutr* 2000 August;130(8S Suppl):2120S-6S.
148. Arteel GE, Schroeder P, Sies H. Reactions of peroxynitrite with cocoa procyanidin oligomers. *J Nutr* 2000 August;130(8S Suppl):2100S-4S.